2008

Hoschler K, Gopal R, Andrews N, Saville M, Pepin S, Wood J, Zambon M. Cross-neutralisation of antibody elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains. Influenza and other respiratory viruses. 2008: 1(5-6): 199-206.

Harvey R, Wheeler JX, Wallis CL, Robertson JS, Engelhardt OG . [ ] Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine. 2008 Dec 2 ; 26, (51): 6550-6554 [Epub 2008 Oct 7]

Inglis S, Wood J, Minor P. Open debate could slow flu vaccine development. Nature. 2008 Aug 21; 454(7207):939 .

Joung J, Robertson JS, Griffiths E, Knezevic I; WHO Informal Consultation Group. ( ) WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals. 2008 Jul;36(4):269-76. Epub 2008 Jan 22.

 

2007

Wood JM, Robertson JS . Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza and Other Respiratory Viruses. 2007; 1(1), 5-9.

Sharpe M, Lynch D, Topham S, Major D, Wood J, Loudon P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery.
Vaccine. 2007 Aug 21;25(34):6392-8. Epub 2007 Jun 28.

Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis. 2007 Jun 1;195(11):1598-606. Epub 2007 Apr 17 .

Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine. 2007 May 16;25(20):4056-63. Epub 2007 Feb 27.

WHO Writing Team (Chung PH, Mumford E, Perdue M, Prosenc K, Zambon M, Peiris M , Perkins M, Wood J, Klimov A, Meijer A, Jennings L). Expert consultation on diagnosis of H5N1 avian flu inflection in humans. Influenza and Other Respiratory Viruses. 2007; 1(4): 131-138.

Whitely A, Major D, Legastellois I, Campitelli L, Donatelli I, Thompson CI, Zambon MC, Wood JM, Barclay WS. Generation of candidate human influenza vaccine strains in cell culture – rehearsing the European response to an H7N1 pandemic threat. Influenza and other Respiratory viruses. 2007; 1(4): 157-166.

Shin J, Wood D, Robertson J, Minor P, Peden K, . WHO Informal Consultation Group. . WHO informal consultation on the application of molecular methods to assure the quality, safety and efficacy of vaccines, Geneva, Switzerland, 7-8 April 2005. (Conference report). Biologicals. 2007; 35(1): 63-71.

 

2006

Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
Lancet. 2006 Sep 16;368(9540):991-7.

Cassetti MC, Katz JM, Wood J. Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines. Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, 25 January 2005. Vaccine. 2006 Jan 30;24(5):541-3. No abstract available.

Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.
Lancet. 2006 May 20;367(9523):1657-64.

Deng T, Engelhardt OG, Thomas B, Akoulitchev AV, Brownlee GG, Fodor E. Role of ran binding protein 5 in nuclear import and assembly of the influenza virus RNA polymerase complex.
J Virol. 2006 Dec;80(24):11911-9. Epub 2006 Sep 27.

Robertson JS , Griffiths E. Assuring the quality, safety, and efficacy of DNA vaccines. Methods Mol Med. 2006;127:363-74. Review.

Robertson JS . Bovine serum--regulatory issues. Dev Biol (Basel). 2006;123:269-72; discussion 291-308.

Robertson JS . Changes in biological source material. Biologicals. 2006 Mar;34(1):61-3. Epub 2005 Dec 2. Review.

Sewerin K, Shacter E, Robertson J, Wallerius C. Changes to biological source material. Biologicals. 2006; 34(1): 71-72

 

2005

Cassetti MC, Couch R, Wood J, Pervikov Y. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004.
Vaccine. 2005 Feb 18;23(13):1529-33.

Nicolson C, Major D, Wood JM, Robertson JS . Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine. 2005 Apr 22;23(22):2943-52.

Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.
J Infect Dis. 2005 Apr 15;191(8):1210-5. Epub 2005 Mar 14.

Daly LM, Johnson PA, Donnelly G, Nicolson C, Robertson J, Mills KH. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120.
Vaccine. 2005 Jan 4;23(7):963-74.

The World Health Organization Global Influenza Program Surveillance Network (Robertson J and Wood J among ~50 authors) Evolution of H5N1 avian influenza viruses in Asia. Emerging Infectious Diseases. 2005; 11: 1515-1521.

 

2004

Wood JM , Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.
Nat Rev Microbiol. 2004 Oct;2(10):842-7. Review.

Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic.
Lancet Infect Dis. 2004 Aug;4(8):499-509. Review.

Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.
Virus Res. 2004 Jul;103(1-2):91-5.

Wood JW , Webster RG, Webby RJ, Robertson JS, Katz J, Levandowski RA. Grohmann G, Cox N, Hay AJ, Tashiro M, Hampson A, Gust I, Stöhr K. Influenza pandemic vaccines; the imminent challenges from a technical and regulatory perspective. Options for the Control of Influenza V (Kawaoka Y, ed), Elsevier B.V., International Congress Series. 2004; 1263, pp 51-54.

Robertson JS. (2004) Editor: PDA/EMEA European Virus Safety Forum. Dev Biol (Basel). 2004; 118 .

 

2003

Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.
Vaccine. 2003 Apr 2;21(15):1687-93.

Wood JM , Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines.
Dev Biol (Basel). 2003;115:9-16.

Stephenson I, Nicholson KG, Gluck R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.
Lancet. 2003 Dec 13;362(9400):1959-66.

Nicholson KG, Wood JM, Zambon M. Influenza.
Lancet. 2003 Nov 22;362(9397):1733-45. Review.

Liu M, Wood JM, Ellis T, Krauss S, Seiler P, Johnson C, Hoffmann E, Humberd J, Hulse D, Zhang Y, Webster RG, Perez DR. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics.
Virology. 2003 Sep 30;314(2):580-90.

Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.
J Med Virol. 2003 Jul;70(3):391-8.

Robertson JS . Viruses and assuring viral safety. Dev Biol (Basel). 2003;113:73-7.

Wood JM , Levandowski RA. The influenza vaccine licensing process.
Vaccine. 2003 May 1;21(16):1786-8.

 

2002

Wood JM . Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine. 2002 Dec 20; 20(Supplement 5): B40-B44.

Wood JM , Nicholson KG, Stephenson I, Zambon M, Newman RW, Major DL, Podda A. Experience with the clinical development of influenza vaccines for potential pandemics.
Med Microbiol Immunol. 2002 Dec;191(3-4):197-201. Epub 2002 Sep 11.

Wood JM, Major D, Newman RW, Dunleavy U, Nicolson C, Robertson JS, Schild GC. Preparation of vaccines against H5N1 influenza.
Vaccine. 2002 May 15;20 Suppl 2:S84-7.

Choudhri Y, Walop W, Squires S, Tam T, King A, Skowronski D, Warrington R, Wood J. ORS during the 2000-2001 influenza vaccination season.
Can Commun Dis Rep. 2002 Sep 1;28(ACS-6):2-8.

Gambarian AS, Iamnikova SS, L'vov DK, Robertson JS, Webster RG, Matrosovich MN. Differences in receptor specificity between the influenza A viruses isolated from the duck, chicken, and human
Mol Biol (Mosk). 2002 May-Jun;36(3):542-9. Russian.

Cox RJ, Mykkeltvedt E, Robertson J, Haaheim LR. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication.
Scand J Immunol. 2002 Jan;55(1):14-23.

Gambaryan AS, Iamnikova SS, Lvov DK, Robertson,JS, Webster RG Matrosovich MN. [ Comparison of the receptor specificity of influenza viruses circulating in humans, ducks, and chickens. Molekulyarnaya Biologiya (Molecular Biology) 2002; 36(3): 542-549 .

 

2001

Wood JM . Developing vaccines against pandemic influenza.
Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1953-60.

Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.
Lancet. 2001 Jun 16;357(9272):1937-43.

Robertson JS . Retroviral aspects of the characterisation of avian and mammalian cell substrates. Dev Biol (Basel). 2001;106:417-22; discussion 422-4, 465-75.

Robertson JS , Griffiths E. Assuring the quality, safety, and efficacy of DNA vaccines. Mol Biotechnol. 2001 Feb;17(2):143-9. Review. http://www.springerlink.com/content/vp0p2k4372287358/

Robertson JS, Cichutek K. From Research Data to Clinical Trials. In, “Plasmids for Therapy and Vaccination” (M Schleef, ed). Wiley-VCH, Weinheim. 2001; 255-260.

Wood JM , Nicholson KG, Zambon M, Hinton R, Major DL, Newman RW, Dunleavy U, Melzak D, Robertson JS, Schild GC. Developing vaccines against potential pandemic influenza viruses. In, “Options for the Control of Influenza IV”. (ADME Osterhaus, et al., eds.). International Congress Series. Elsevier Science B.V., Amsterdam. 2001; 1219: 751-759.

 

2000

Johnson PA, Conway MA, Daly J, Nicolson C, Robertson J, Mills KH. Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses.
J Gen Virol. 2000 Jul;81(Pt 7):1737-45.

Robertson JS , Cichutek K. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements. Dev Biol (Basel). 2000;104:53-6.

Brown F, Cichutek K , Robertson JS. (Editors) Development and clinical progress of DNA vaccines. Developments in Biologicals, Karger, Basel. 2000; 104.

Wood JM, Major D, Daly J, Newman RW, Dunleavy U, Nicolson C, Robertson JS, Schild GC , Lee-Lin YN. Vaccines against H5N1 influenza.
Vaccine. 2000 ;18:579-80.

 

1999

Wood JM, Dunleavy U, Newman RW, Riley AM, Robertson JS, Minor PD . The influence of the host cell on standardisation of influenza vaccine potency.
Dev Biol Stand. 1999;98:183-8; discussion 197.

Snacken R, Kendal AP, Haaheim LR, Wood JM. The next influenza pandemic: lessons from Hong Kong, 1997.
Emerg Infect Dis. 1999 Mar-Apr;5(2):195-203. Review.

Robertson JS. An overview of host cell selection.
Dev Biol Stand. 1999;98:7-11; discussion 73-4. Review.

Gambaryan AS, Robertson JS, Matrosovich MN. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses.
V irology. 1999 Jun 5;258(2):232-9.

Minor PD . Inactivated influenza vaccines prepared in cell culture. Summary and recommendations.
Dev Biol Stand. 1999;98:201-3.

Castle P, Robertson JS. Summary and conclusion. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals. Dev Biol Stand. 1999;99:191-6. Review.

Brown F, Robertson JS, Schild GC , Wood JM. Inactivated influenza vaccines prepared in cell culture. (Editors) Developments in Biological Standardization, Karger, Basel, 1999; 98.

Robertson JS, Griffiths E. Assuring the quality, safety, and efficacy of DNA vaccines. In: “DNA Vaccines: Methods and Protocols” (Lowrie DB & Whalen RG, eds). Methods in Molecular Medicine, Humana Press, Totowa, New Jersey. 1999; 499-508.